Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report

Xue,Xinying; Xue,Qingliang; Liu,Yuxia; Pan,Lei; Wang,Kaifei; Zhang,Lina; Wang,Na; Yang,Bing; Wang,Jianxin

doi:10.3892/ol.2013.1212

Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report

Authors:
- Xinying Xue
- Qingliang Xue
- Yuxia Liu
- Lei Pan
- Kaifei Wang
- Lina Zhang
- Na Wang
- Bing Yang
- Jianxin Wang
View Affiliations

Affiliations: Cadres Respiratory Diseases Department of Beijing Shijitan Hospital, Beijing 100038, P.R. China, Department of Respiratory Diseases of Chinese PLA General Hospital, Beijing 100853, P.R. China, Research Department of Chinese Academy of Medical Sciences, Beijing 100864, P.R. China
Published online on: February 27, 2013 https://doi.org/10.3892/ol.2013.1212
Pages: 1599-1600

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gefitinib-induced interstitial lung disease (ILD) is a rare but lethal drug adverse event, which usually leads to the withdrawal of gefitinib and causes complications with anticancer treatment. In this study, gefitinib administration combined with prednisolone in a female with stage IIIb non‑small cell lung cancer (NSCLC) produced a good outcome without inducing ILD. The results suggested that combined administration of gefitinib with glucocorticoids may be an efficient method to treat NSCLC while avoiding complications with ILD.

View Figures

View References

1	Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S and Corona G: Pharmacology of epidermal growth factor inhibitors. Int J Biol Markers. 22(1 Suppl 4): S24–S39. 2007.PubMed/NCBI
2	Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non small-cell lung cancer. J Natl Cancer Inst. 97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
3	Ieki R, Saitoh E and Shibuya M: Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J. 22:179–181. 2003. View Article : Google Scholar : PubMed/NCBI
4	Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T and Nukiwa T: Severe acute interstitial pneumonia and gefitinib. Lancet. 361:137–139. 2003. View Article : Google Scholar : PubMed/NCBI
5	Cohen MH, Williams GA, Sridhara R, Chen G and Pazdur R: FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 8:303–306. 2003. View Article : Google Scholar : PubMed/NCBI
6	Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, et al; Japan Thoracic Radiology Group. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI
7	Gupta A and Raina V: Geftinib. J Cancer Res Ther. 6:249–254. 2010. View Article : Google Scholar
8	Suzuki M, Asahina H, Konishi J, Yamazaki K and Nishimura M: Recurrent gefitinib-induced interstitial lung disease. Intern Med. 47:533–536. 2008. View Article : Google Scholar : PubMed/NCBI
9	Gemma A: Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents. J Nippon Med Sch. 76:4–8. 2009. View Article : Google Scholar : PubMed/NCBI